eBook Annual Reports in Medicinal Chemistry, 1st Edition

  • Published By:
  • ISBN-10: 0124171516
  • ISBN-13: 9780124171510
  • DDC: 615.19
  • Grade Level Range: College Freshman - College Senior
  • 672 Pages | eBook
  • Original Copyright 2013 | Published/Released June 2014
  • This publication's content originally published in print form: 2013
  • Price:  Sign in for price



Annual Reports in Medicinal Chemistry provides timely and critical reviews of important topics in medicinal chemistry together with an emphasis on emerging topics in the biological sciences, which are expected to provide the basis for entirely new future therapies. Annual Reports in Medicinal Chemistry provides timely and critical reviews and this volume covers a important topicsĀ such as drug Discovery, Idiopathic Pulmonary Fibrosis and Neuraminidase Inhibitors.

Table of Contents

Front Cover.
Half Title Page.
Title Page.
Copyright Page.
1: Personal Essays.
2: Challenges in Drug Discovery at Schering–Plough Research Institute: A Personal Reflection.
3: My Perspective on Time, Managers—and Scientific Fun.
4: A Career in Medicinal Chemistry—A Journey in Drug Discovery.
5: Central Nervous System Diseases.
6: Selective Inhibitors of PDE2, PDE9, and PDE10: Modulators of Activity of the Central Nervous System.
7: Beyond Secretases: Kinase Inhibitors for the Treatment of Alzheimer’s Disease.
8: Orexin Receptor Antagonists in Development for Insomnia and CNS Disorders.
9: Cardiovascular and Metabolic Diseases.
10: Discovery and Development of Prolylcarboxypeptidase Inhibitors for Cardiometabolic Disorders.
11: Molecular Targeting of Imaging and Drug Delivery Probes in Atherosclerosis.
12: Oral GLP-1 Modulators for the Treatment of Diabetes.
13: Inflammation Pulmonary GI Diseases.
14: Recent Advances in the Discovery and Development of CCR1 Antagonists.
15: Emerging Targets for the Treatment of Idiopathic Pulmonary Fibrosis.
16: Targeting the Nuclear Hormone Receptor RORγt for the Treatment of Autoimmune and Inflammatory Disorders.
17: Oncology.
18: Recent Advances in Small-Molecule Modulation of Epigenetic Targets: Discovery and Development of Histone Methyltransferase and Bromodomain Inhibitors.
19: Inhibition of Ubiquitin Proteasome System Enzymes for Anticancer Therapy.
20: Targeting Protein–Protein Interactions to Treat Cancer—Recent Progress and Future Directions.
21: Infectious Diseases.
22: Recent Progress in the Discovery of Neuraminidase Inhibitors as Anti-Influenza Agents.
23: Novel Therapeutics in Discovery and Development for Treatment of Chronic HBV Infection.
24: Special Challenges to the Rational Design of Antibacterial Agents.
25: Topics in Biology.
26: Recent Advances in Small Molecule Target Identification Methods.
27: Neuroinflammation in Mood Disorders: Mechanisms and Drug Targets.
28: Topics in Drug Design and Discovery.
29: Inhibitors of hERG Channel Trafficking: A Cryptic Mechanism for QT Prolongation.
30: Recent Progress in Small-Molecule Agents Against Age-Related Macular Degeneration.
31: Synthetic Macrocycles in Small-Molecule Drug Discovery.
32: Glossary of Terms Used in Medicinal Chemistry Part II (IUPAC Recommendations 2013).
33: Case Histories and NCEs.
34: Case History: Xalkori™ (Crizotinib), a Potent and Selective Dual Inhibitor of Mesenchymal Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) for Cancer Treatment.
35: Case History: Vemurafenib, a Potent, Selective, and First-in-Class Inhibitor of Mutant BRAF for the Treatment of Metastatic Melanoma.
36: New Chemical Entities Entering Phase III Trials in 2012.
37: To Market, To Market—2012.
Keyword Index.
Cumulative Chapter Titles Keyword Index, Volume 1 – 48.
Cumulative NCE Introduction Index, 1983–2012.
Cumulative NCE Introduction Index, 1983–2012 (by Indication).
Color Plate.